Matters Concerning Controlling Shareholders, Etc.
Filed with TSE · · 3 pages · English
Watch Sumitomo Pharma Co.Ltd's latest callSumitomo Pharma (Tokyo:4506) Q1 2026 Earnings Call · Replay · Aug 4Read the transcript of Sumitomo Pharma (Tokyo:4506) Q1 2026 Earnings CallSumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE, the "Company") hereby announces the following matters concerning the controlling shareholder, etc. in relation to Sumitomo Chemical Co., Ltd., which is the parent company of the Company. 1. Name of the Parent Company, Controlling Shareholder (Ex
Sumitomo Pharma Co.Ltd. on 6ix
Earlier from Sumitomo Pharma Co.Ltd
- Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
- Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change
- New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
- May 13, 2026 Conference on FY2025 Financial Results transcript（PDF/5,711KB）
- Sumitomo Pharma: Posted Conference on FY2025 Financial Results
Later from Sumitomo Pharma Co.Ltd
- Presentation Material (Conference on Q1 FY2026 Financial Results)
- Regarding a Report Concerning Sumitomo Pharma
- Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The 116 billion yen Swiss Shuffle”
- Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report)
- Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements
Follow Sumitomo Pharma Co.Ltd into a list and get an email when it puts out news.
Follow Sumitomo Pharma Co.Ltd